Managed Care Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Managed Care Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Brown University
Dual reuptake inhibitors incur lower tachyphylaxis rates than SSRIs
August 16th, 2005
Dual reuptake inhibitor-based treatment for depression is associated with a lower tachyphylaxis rate than selective serotonin reuptake inhibitor (SSRI)-based therapy. The possibility that SSRIs "may be associated with higher relapse rates than other antidepressants during maintenance treatment (tachyphylaxis) has been discussed for years, but to date there is little or no empirical evidence confirming this phenomenon," psychiatrists in the United States explained. In a recent study, M.A. Posternak and coauthors at Brown University "systematically assessed prior antidepressant treatment history in a cohort of depressed patients who presented for...
Source: Managed Care Business Week (2005-08-16)
|
